BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cells » MSCs » Page 31

Mesenchymal Stem Cells (MSCs)

Mesenchymal stem cells (MSCs) are a well-characterized population of adult stem cells that can differentiate into a variety of cell types (chondrocytes, osteoblasts, adipocytes, myocytes, and more).

Cynata Advances Development of Cymerus™ MSCs for the Treatment of Asthma

By Leave a Comment

  • Final report of initial preclinical study confirms Cymerus™ MSCs have significant beneficial effects on all three key components of asthma: airway hyper-responsiveness, inflammation and airway remodelling
  • Additional preclinical study expected to pave the way for a potential clinical trial

Cynata TherapeuticsMelbourne, Australia; 2 March 2017 – Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), has signed an agreement with the Monash Lung Biology Network, a consortia involving researchers from the Monash Biomedicine Discovery Institute and Department of Pharmacology at Monash University, Melbourne, to conduct a further preclinical study to support the use of CymerusTM mesenchymal stem cells (MSCs) for the treatment of asthma. [Read more…]

Treatment Benefit Confirmed in Final Report of GvHD Preclinical Study Using Cynata’s MSCs

By Leave a Comment

  • Robust survival benefit resulting from treatment with CYP-001 confirmed

  • Substantial body of data generated to support mechanism of action of CYP-001 in GvHD

Cynata TherapeuticsMelbourne, Australia; 6 February 2017 — Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced today that it has received a final report of the proof of concept study of its lead CymerusTM mesenchymal stem cell (MSC) product for graft-versus-host disease (GvHD), CYP-001, in a humanised mouse model of GvHD, which was conducted under the supervision of Associate Professor Lisa Minter at the University of Massachusetts Amherst (UMass), USA. [Read more…]

Cynata Therapeutics Secures $6M in Capital Raise, $10M with Payment from FUJIFILM

By Leave a Comment

Cynata Successfully Completes Capital Raising

Cynata TherapeuticsMelbourne, Australia; 23 January 2017: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), has successfully completed a placement of approximately 9.23 million fully-paid ordinary shares at a price of $0.65, for gross proceeds of A$6.0 million before costs (“Placement”). The Placement was made to existing and new sophisticated and institutional investors. Settlement of the Placement, which was heavily over-subscribed, is expected to occur on or about 27 January 2017 with the shares to be issued on 30 January 2017. The Placement shares will be issued under Cynata’s existing placement capacity under Listing Rules 7.1 and 7.1A, and accordingly will not require shareholder approval.  [Read more…]

Regeneus Finalizes Terms with AGC, $5.5M Plus Future Payments of $11M

By Leave a Comment

Regeneus receives upfront payment of US$5.5m from AGC

RegeneusRegeneus Ltd (ASX: RGS), a clinical stage regenerative medicine company, today announced it has received US$5.5m from AGC as an upfront payment for the exclusive rights to manufacture Progenza under the terms of the collaboration and licence announced on 29 December 2016.

Regeneus is expected to receive a further US$11m in specific development and approval milestone payments.

Regeneus will be entitled, through its 50 per cent interest in Regeneus Japan, to its share of upfront licence fees, milestone payments and royalties from sub licensing the development and commercialisation of Progenza for osteoarthritis and all other clinical indications in Japan. [Read more…]

Cynata Inks Deal with FUJIFILM, $3.97M Plus Potential Payments of $60M+

By Leave a Comment

Cynata and FUJIFILM Sign Development and Commercialisation Partnership Agreement

  • Fujifilm takes A$3.97 million strategic equity stake in Cynata
  • Parties to collaborate on the further development and commercialisation of Cynata’s lead Cymerus™ therapeutic MSC product CYP-001 for graft-versus-host disease (GvHD)
  • Potential future upfront and milestone payments in excess of A$60 million
  • Double-digit royalties on CYP-001 product net sales
  • Strategic relationship for potential future manufacture of CYP-001 and certain rights to other Cynata technology

[Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0